|Bid||0.00 x 20000|
|Ask||0.00 x 20000|
|Day's Range||32.38 - 32.74|
|52 Week Range||15.24 - 36.64|
|Beta (3Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Medicines Company (NASDAQ: MDCO ) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week. At this point, Medicines Company traders are likely considering ...
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 80 cents. Losses, adjusted for one-time gains and costs, were 62 cents per share. Medicines Co. shares have increased ...
Leading biotech Amgen could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.
On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.
As the market got off to its best two-month start to a year in some three decades herein 2019, insider purchases not surprisingly have ebbed substantially and insider selling has picked up. and is a new name on our insider buying list this week.
This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
CEO of The Medicines Co (NASDAQ:MDCO) Mark Timney bought 26,863 shares of MDCO on 12/17/2018 at an average price of $18.6 a share.
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.
Medicines Co. (MDCO) delivered earnings and revenue surprises of -45.83% and -189.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 75 cents per share. Losses, adjusted for one-time gains and costs, came to 70 cents per share. The results did not meet Wall Street expectations. ...
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios. Olin Corp. (OLN) is trading around $30.27 with a price-sales ratio of 0.8, a price-earnings ratio of 8.2 and a forward price-earnings ratio of 11.6. The company has a market cap of $5.06 billion and the stock price has risen at an annualized rate of 5% over the last 10 years.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.